Quotient renames radiolabelling unit

By Gareth Macdonald

- Last updated on GMT

Quotient Amersham Radiochemicals has been rebranded as Quotient Custom Radiolabelling in the latest stage of two year expansion programme by parent Quotient Bioresearch.

Quotient Bioresearch bought the radiolabelling specialist from GE Healthcare in 2009​ as part of a strategic expansion of its metabolism and carbon-14 (14C) enabled contract drug development capabilities.

Since then Quotient has sought to build the firm’s capabilities with a number of investment, most notably a £15m ($24.7m) radiolabelled compound manufacturing and testing in Cardiff, Wales that became operational last year​.

The name change marks a significant stage in this expansion process according to Stephen Lewinton, MD for Chemistry and Metabolism at Quotient Bioresearch.

The past two years have been particularly exciting for Quotient and it’s with a great sense of accomplishment that we officially change name to Quotient Custom Radiolabelling.

We inherited an enviable legacy from Amersham Radiolabeling Services and through our investment in the business and in the new facility we’re able to provide a fully-integrated quick response service for our customers​.”

The news comes after a busy few weeks of developments and deals for the Quotient group as a whole.

On May 5 Quotient’s clinical unit announced the expansion of its clinical facility in Nottingham in the UK, increasing the number of beds at the facility by 50 per cent to 44.

The firm cited increasing drug industry demand for ADME studies with MD Mark Egerton suggesting the expansion “underlines the strength of our Synthesis-to-Clinic platform.”

More recently Quotient teamed up with disease modelling expert KWS in a deal focused on the development of antimicrobials.

The collaboration combined Quotient Bioresearch’s capabilities in in-vitro ​testing, clinical services and other areas with disease model expertise at KWS BioTest.

Related news

Show more

Related products

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers